NEW ZEALAND DATA SHEET

1 PRODUCT NAME
NITRODERM® TTS 5: 25 mg Transdermal Patch
NITRODERM® TTS 10: 50 mg Transdermal Patch

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1,2,3-Propanetriol trinitrate (= nitroglycerin), 25 mg or 50 mg in a transdermal therapeutic system (TTS). Nitroglycerin is an organic nitrate derivative.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
Flat multilayer system designed to deliver nitroglycerin continuously through a release membrane following application to the skin. The release membrane limits delivery through hyperpermeable skin. The active substance penetrates the skin and thus becomes directly bioavailable to the systemic circulation at relatively constant concentrations during the recommended application period. The following three systems are available:

<table>
<thead>
<tr>
<th>Nitroderm pharmaceutical forms</th>
<th>Nitroderm TTS 5</th>
<th>Nitroderm TTS 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitroglycerin content</td>
<td>25 mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>Drug-releasing area</td>
<td>10 cm²</td>
<td>20 cm²</td>
</tr>
<tr>
<td>Imprint (backing side)</td>
<td>CG</td>
<td>CG</td>
</tr>
<tr>
<td></td>
<td>DOD</td>
<td>DPD</td>
</tr>
<tr>
<td>Colour of the release liner</td>
<td>white to yellowish</td>
<td></td>
</tr>
</tbody>
</table>

The numeric components of the product designations TTS 5 and TTS 10 denote the nominal amount of nitroglycerin in mg delivered by the system per 24 hours.

The remainder of the nitroglycerin in each system serves as a reserve and is not delivered in normal use. After 12 hours, for example, each system has delivered 10% of its original content of nitroglycerin. Since nitroglycerin is released from Nitroderm TTS at a constant rate per cm², the dose administered is related to the size of the drug-releasing area. The nominal rate of nitroglycerin release in vivo is approximately 20-25 microgram/cm².h.
The following cross-sectional diagram shows the composition of Nitroderm TTS.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of angina pectoris

As monotherapy or in combination with other anti-anginal drugs such as beta blockers and/or calcium antagonists.

Treatment of congestive heart failure

As supplementary medication in patients not responding adequately to conventional therapy with digitalis or other positive inotropic agents and diuretics.

4.2 Dosage And Method Of Administration

General rules

Nitroderm TTS is not intended for the immediate relief of acute attacks of angina pectoris; if these occur, rapid-acting nitrate preparations should be used.

The response to nitrate preparations varies from patient to patient; the lowest effective dose should be prescribed. The application site should be changed regularly to prevent local irritation.

Development of tolerance or attenuation of therapeutic effect commonly occurs with prolonged or frequent administration of long acting nitrates, including Nitroderm TTS or other transdermal systems. A patch-off period of 8-12 hours, usually at night, every 24 hours is recommended to overcome tolerance. Clinical trials have shown that in most patients intermittent therapy is more effective than continuous administration. Continuous application of Nitroderm TTS may be appropriate for patients in whom long term clinical responsiveness can be reliably assessed.

Treatment of angina pectoris

Treatment should be initiated with one Nitroderm TTS 5 daily. According to the clinical response the daily dose can then be titrated upwards to:

- one Nitroderm TTS 10 (normal maintenance dose)
- one Nitroderm TTS 10 plus Nitroderm TTS 5
- two Nitroderm TTS 10
Treatment of congestive heart failure

It is recommended that treatment be started in hospital and the patient's haemodynamic status monitored; treatment should also be continued in hospital until the requisite maintenance dosage has been established.

The optimal dosage should be determined in the light of the clinical response, the side effects encountered, and careful monitoring for signs of overdosage such as a fall in blood pressure and tachycardia.

Special populations

Use in the elderly

No specific information on use in the elderly is available; however, there is no evidence to suggest that the dosage needs to be adjusted in elderly patients.

Use in children

Not enough is known about the effects of Nitroderm TTS in children, which means that it cannot be recommended for use in this age group.

4.3 Contraindications

Known hypersensitivity to nitroglycerin, and related organic nitrates or any excipient of Nitroderm TTS. Acute circulatory failure associated with marked hypotension (shock). Conditions associated with elevated intracranial pressure. Myocardial insufficiency due to obstruction, as in aortic or mitral stenosis or constrictive pericarditis.

Concomitant use of Nitroderm TTS and phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil is contraindicated, because PDE5 inhibitors may amplify the vasodilatory effects of Nitroderm TTS resulting in severe hypotension.

4.4 Special Warnings And Precautions For Use

Warnings

As with other nitrate preparations, when transferring the patient on long term therapy to another form of medication, nitroglycerin should be gradually withdrawn and overlapping treatment started.

The Nitroderm TTS patch contains an aluminium layer. Therefore Nitroderm TTS must be removed before applying magnetic or electrical fields to the body during procedures such as MRI (Magnetic Resonance Imaging), cardioversion or DC defibrillation, or diathermy treatment.

In cases of recent myocardial infarction or acute heart failure, treatment with Nitroderm TTS should be carried out cautiously under strict medical surveillance and/or haemodynamic monitoring.
Precautions

Hypoxaemia

Caution should be exercised in patients with arterial hypoxaemia due to severe anaemia, because in such patients the biotransformation of nitroglycerin is reduced. Similarly, caution is called for in patients with hypoxaemia and ventilation/perfusion imbalance due to lung disease or ischaemic heart failure. Patients with angina pectoris, myocardial infarction, or cerebral ischaemia frequently suffer from abnormalities of the small airways (especially alveolar hypoxia). Under these circumstances vasoconstriction occurs within the lung to shift perfusion from areas of alveolar hypoxia to better ventilated regions of the lung. As a potent vasodilator, nitroglycerin could reverse this protective vasoconstriction and thus result in increased perfusion of poorly ventilated areas, worsening of the ventilation/perfusion imbalance, and a further decrease in the arterial partial pressure of oxygen.

Hypertrophic cardiomyopathy

Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy.

Increased angina

The possibility of increased frequency of angina during patch-off periods should be considered. In such cases the use of additional anti anginal therapy is desirable.

Tolerance to sublingual nitroglycerin

As tolerance to nitroglycerin patches develops, the effect of sublingual nitroglycerin on exercise tolerance may be partially diminished.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Interactions resulting in a concomitant use contraindicated

Concomitant administration of Nitroderm TTS and PDE5 inhibitors such as sildenafil [ potentiats the blood-pressure-lowering effect of Nitroderm TTS.,

Interactions to be considered

Concomitant treatment with calcium antagonists, ACE inhibitors, beta-blockers, diuretics, antihypertensives, tricyclic antidepressants and major tranquillisers may potentiate the blood pressure-lowering effect of Nitroderm TTS, as may alcohol.

Concurrent administration of Nitroderm TTS with dihydroergotamine may increase the bioavailability of dihydroergotamine. This warrants special attention in patients with coronary artery disease, because dihydroergotamine antagonises the effect of nitroglycerin and may lead to coronary vasoconstriction.

The possibility that the ingestion of acetylsalicylic acid and non-steroidal anti-inflammatory drugs might diminish the therapeutic response to Nitroderm TTS cannot be excluded.
FERTILITY, PREGNANCY AND LACTATION

Women of Child-bearing Potential and Contraceptive Measures

There is no data supporting any special recommendations in women of child-bearing potential.

Pregnancy

Like any drug, Nitroderm TTS should be employed with caution during pregnancy, especially in the first 3 months.

Breast-feeding

It is not known whether the active substance passes into the breast milk. The benefits for the mother must be weighed against the risks for the child.

Fertility

There is no data available on the effect of Nitroderm TTS on fertility in humans.

Effects on ability to drive and use machines

When driving or using machines, patients should be aware that Nitroderm TTS, especially at the start of treatment, may cause dizziness.

Undesirable effects

Adverse effects listed by MedDRA System-Organ Class (SOC). Within each System-Organ Class the adverse drug reactions are ranked by frequency, with the most frequent first. Within each frequency grouping, adverse drug reactions are ranked in order of decreasing seriousness. In addition, the corresponding frequency category, using the following convention (CIOMS III: Very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1000, < 1/100); rare (≥ 1/10,000, < 1/1000); very rare (< 1/10,000), including isolated reports

Table 1

<table>
<thead>
<tr>
<th>Nervous system disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common:</td>
</tr>
<tr>
<td>Headache&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Very rare:</td>
</tr>
<tr>
<td>Dizziness</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiac disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare:</td>
</tr>
<tr>
<td>Tachycardia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vascular disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare:</td>
</tr>
<tr>
<td>Orthostatic hypotension, flushing&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gastrointestinal disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common:</td>
</tr>
<tr>
<td>Nausea, vomiting</td>
</tr>
</tbody>
</table>
Like other nitrate preparations, Nitroderm TTS commonly causes dose-dependent headaches due to cerebral vasodilatation. These often regress after a few days despite the maintenance of therapy. If headaches persist during intermittent therapy, they should be treated with mild analgesics. Unresponsive headaches are an indication for reducing the dosage of nitroglycerin or discontinuing treatment.

A slight reflex-induced increase in heart rate can be avoided by resorting, if necessary, to combined treatment with a beta-blocker.

Upon removal of the patch, any slight reddening of the skin will usually disappear within a few hours. The application site should be changed regularly to prevent local irritation.

The following adverse drug reactions have been derived from post-marketing experience with Nitroderm TTS via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Within each System-Organ Class, adverse drug reactions are presented in order of decreasing seriousness.

- Cardiac disorders: palpitation
- Skin and subcutaneous tissue disorders: rash generalized

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/}

4.9 Overdose

Signs

High doses of nitroglycerin may lead to severe hypotension and reflex tachycardia or to collapse and syncope. Methaemoglobinemia has also been reported following accidental overdosage. However, with Nitroderm TTS, the release membrane will reduce the likelihood of overdosage.

Management

The nitrate effect of Nitroderm TTS can be rapidly terminated simply by removing the system(s).
Hypotension or collapse can be treated by elevation or, if necessary, compression bandaging of the patient’s legs.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic Group and ATC

Pharmacotherapeutic group: Vasodilators used in cardiac diseases

ATC code: C01DA02

Mechanism of Action

Pharmacodynamic properties (PD)

Nitroglycerin relaxes smooth muscle throughout the body. In the vascular system it acts chiefly on the systemic veins and accessorially on the large coronary arteries.

Nitroglycerin at low doses is bioactivated by mitochondrial aldehyde dehydrogenase activity, and is converted to nitrites and denitrated metabolites (1,2-glyceryl dinitrate,1-3-glyceryl dinitrate) by glutathione-dependent organic nitrate reductase. Nitrite is further activated by cytochrome oxidase or acidic disproportionation in the intermembrane space (H+), finally yielding nitric oxide (NO) or a related species, which activate soluble guanylyl cyclase and trigger cyclic guanosine monophosphate (cGMP) signaling via cGMP-dependent protein kinase, which causes relaxation. Glyceryl dinitrate, mononitrate and nitroglycerin at high doses are bioactivated by P450 enzyme(s) in the smooth endoplasmic reticulum directly yielding NO which causes relaxation.

In angina pectoris a fundamental mechanism of action of nitroglycerin is an increase in venous capacitance (venous pooling) leading to a decreased return of blood to the heart. This lowers left ventricular end-diastolic pressure (preload) and hence filling volume, which in turn lowers the myocardial oxygen requirement at rest and especially during exercise, hence enhancing exercise capacity.

In the coronary arterial circulation nitroglycerin dilates both extramural conductance and small resistance vessels. The drug appears to redistribute coronary blood flow to ischaemic subendocardium by selectively dilating large epicardial vessels. It can also dilate stenoses caused by eccentric atheroma. In addition, nitroglycerin relaxes vasospasm, whether spontaneous or induced by ergonovine.

Nitroglycerin dose-dependently dilates the arteriolar vascular bed, thereby lowering systemic vascular resistance (afterload) and left ventricular systolic wall tension, and further reducing myocardial oxygen consumption.

Dosing regimens for most chronically used drugs aim for plasma concentrations that continuously exceed the minimally effective concentration, but this strategy is probably inappropriate for organic nitrates. Although some well-controlled clinical trials using exercise tolerance testing showed that efficacy is maintained when patches are worn continuously, most of them reported the development of tolerance (i.e. attenuation of effect as measured by exercise
testing) within the first day. As might be expected on pharmacological grounds, tolerance is also observed with high transdermal doses exceeding 4 mg/h.

Efficacy of organic nitrates is restored after a nitrate-free interval. The shortest drug-free interval sufficient to restore response has not been defined. Intervals of 8 to 12 hours are known to be sufficient, shorter intervals have not been fully studied. When administered according to an intermittent regimen, doses of Nitroderm TTS delivering 0.4-0.8 mg/h (20-40 cm²) have shown increased exercise capacity for 8 to 12 hours.

Controlled clinical trial data suggest that intermittent use of nitrates may be associated with a decrease in exercise tolerance compared with placebo during the last part of the nitrate-free interval; the clinical relevance of this observation is unknown (see Special warnings and special precautions for use).

In chronic heart failure the venodilator action of nitroglycerin lowers the elevated left ventricular filling pressure, while maintaining or slightly increasing cardiac output. In this indication the beneficial effects of nitroglycerin are restricted to severe heart failure with predominant symptoms of pulmonary venous congestion due to a pronounced increase in left ventricular filling pressure. Where improved stroke volume is desired, combined treatment with an arterial vasodilator such as hydralazine is recommended.

5.1 Pharmacokinetic properties

Nitroderm TTS

Absorption

Following single application of Nitroderm TTS, the plasma concentrations of nitroglycerin reach a plateau within 2 hours, which is maintained over the recommended application period. The height of this plateau is directly proportional to the size of the system’s drug-releasing area. The same plasma levels are attained regardless of whether the system is applied to the skin of the upper arm, pelvis, or chest. Levels fall rapidly after patch removal. Accumulation does not occur on repeated application of Nitroderm TTS.

Nitroglycerin

Distribution

The plasma protein binding fraction is 61-64%, for nitroglycerin, 23% and 11% for 1, 2-glyceryl dinitrate and 1, 3-glyceryl dinitrate respectively.

Metabolism

The active substance is rapidly biotransformed to glyceryl dinitrates and mononitrates by glutathione-dependent organic nitrate reductase in the liver. In addition, and probably more importantly, in vitro studies have shown that the human erythrocyte is also a site of biotransformation via a sulfhydryl-dependent enzymatic process and interaction with reduced haemoglobin. In human erythrocytes, the reduced haemoglobin level seems to play a major role in metabolic activity, and caution should therefore be exercised in patients with anaemia. In animal studies it has been found that extrahepatic vascular tissues (femoral vein, inferior vena cava, aorta) likewise play an important role in nitroglycerin metabolism, a finding which is consistent with the large systemic clearance seen with nitrates. It has also been shown in vitro that the biotransformation of nitroglycerin occurs concurrently with vascular smooth muscle
relaxation; this observation is consistent with the hypothesis that nitroglycerin biotransformation is involved in the mechanism of nitroglycerin-induced vasodilatation.

**Excretion**

Nitroglycerin is excreted renally as dinitrate and mononitrate metabolites, glucuronide conjugates and glycerol. The elimination half-lives of nitroglycerin, 1,2-glyceryl dinitrate and glyceryl mononitrates are 10, 30-60, 5-6 minutes respectively.

**5.2 Preclinical safety data**

**Mutagenicity**

Standard mutagenicity tests provided contradictory results in vitro. Cell culture and in vivo studies revealed no evidence of mutagenic activity of nitroglycerin, and therefore its use is considered devoid of genotoxic potential at exposures relevant to man.

**Carcinogenicity**

Dietary studies in rodents led to the conclusion that nitroglycerin has no carcinogenic effects relevant for the therapeutic dose range in man.

**Reproduction toxicity**

Animal teratology studies have not been conducted with nitroglycerin transdermal systems. Conventional reproduction studies involving the oral, intravenous, intraperitoneal and dermal (as ointment) administration routes of nitroglycerin have been performed in rats and rabbits. Nitroglycerin showed no teratogenic potential in these animals.

**6 PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Silica aerogel, silicone oil 360 medical adhesive.

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

3 years.

**6.4 Special precautions for storage**

Do not store above 30°C.

Nitroderm TTS should be kept out of the reach and sight of children both before and after use.

**6.5 Nature and contents of container**

- Nitroderm TTS 5: Packs containing 30 patches
- Nitroderm TTS 10: Packs containing 30 patches.

6.6 Special precautions for disposal and handling

Each Nitroderm TTS patch is sealed in a separate sachet with a tear-off edge to facilitate removal. After removing the white protective backing, apply the Nitroderm TTS patch to a clean, non-hairy, dry area of intact skin on the trunk or upper arm. Hold the patch in position for 10-20 seconds with the palm of the hand. Switch application sites daily, wait several days before using the same area again.

7 MEDICINE SCHEDULE

Prescription Medicine

8 SPONSOR

Novartis New Zealand Limited

PO Box 99102
Newmarket,
Auckland 1149
Telephone: 0800 354 335

9 DATE OF FIRST APPROVAL

10 March 1983

10 DATE OF REVISION OF THE TEXT

31 August 2020

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 8 - SPONSOR</td>
<td>Removed Sponsor’s old address</td>
</tr>
</tbody>
</table>

(Internal use only: ntd110920iNZ based on CDS dated 30-June-2011)